ADC Therapeutics Announces Full Exercise of Underwriters’ Option to Purchase Additional Common Shares
ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and...